{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:58:25Z","timestamp":1790614705152,"version":"4.1.0"},"reference-count":17,"publisher":"Pan American Health Organization","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,31]]},"abstract":"<title>ABSTRACT<\/title>\n                  <sec>\n                    <title>Objective.<\/title>\n                    <p>To describe how Grenada leveraged the HEARTS in the Americas standardized clinical pathway to strengthen procurement of a single-pill fixed-dose antihypertensive and align prescribing and procurement across public and private sectors.<\/p>\n                  <\/sec>\n                  <sec>\n                    <title>Methods.<\/title>\n                    <p>Grenada adopted a national hypertension clinical pathway specifying a single-pill fixed-dose combination of telmisartan\/amlodipine with chlorthalidone as preferred therapy. Implementation strategies included integration of pathway medicines into the essential medicines list and procurement systems; engagement of clinical and procurement leadership; dissemination to private providers; and engagement with private pharmacies. A descriptive analysis was conducted using predefined indicators aligned with adoption, feasibility, acceptability, and public\u2013private alignment using survey data, program documents, procurement records, and routine reports.<\/p>\n                  <\/sec>\n                  <sec>\n                    <title>Results.<\/title>\n                    <p>Integration of the standardized regimen into procurement processes supported availability of telmisartan\/amlodipine and chlorthalidone in public primary care facilities, although supply gaps persisted. Adoption of a single national pathway supported standardized prescribing, forecasting, and centralized procurement. Dissemination to private clinicians and pharmacies contributed to uptake in the private sector, with pharmacies independently procuring pathway medicines, supporting continuity of care across sectors, although alignment remained incomplete. Facilitators included early stakeholder engagement, alignment between clinical and procurement leadership, and regimen simplification. Limitations included data system gaps and supply chain constraints.<\/p>\n                  <\/sec>\n                  <sec>\n                    <title>Conclusions.<\/title>\n                    <p>A standardized clinical pathway can strengthen procurement and promote public\u2013private alignment in hypertension care. Addressing supply chain constraints remains essential for sustained access and continuity of treatment, with lessons applicable to other small island developing states implementing HEARTS.<\/p>\n                  <\/sec>","DOI":"10.26633\/rpsp.2026.76","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T14:29:06Z","timestamp":1788186546000},"page":"1","source":"Crossref","is-referenced-by-count":1,"title":["Strengthening access to antihypertensive medicines through HEARTS in the Americas: the Grenada experience"],"prefix":"10.26633","volume":"50","author":[{"given":"Kerry-Ann","family":"Renaud-Thomas","sequence":"first","affiliation":[{"name":"Ministry of Health, St. George, Grenada"},{"name":"smophc@health.gov.gd"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Mark","sequence":"additional","affiliation":[{"name":"Ministry of Health, St. George, Grenada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Isaac","sequence":"additional","affiliation":[{"name":"Ministry of Health, St. George, Grenada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taraleen","family":"Malcolm","sequence":"additional","affiliation":[{"name":"Pan American Health Organization, Port of Spain, Trinidad and Tobago"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Charles","sequence":"additional","affiliation":[{"name":"Ministry of Health, St. George, Grenada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11167","reference":[{"key":"ref1","unstructured":"Pan American Health Organization. Noncommunicable diseases in the Region of the Americas: facts and figures. Washington, D.C.: PAHO; 2019. Available from: https:\/\/iris.paho.org\/handle\/10665.2\/51483."},{"key":"ref2","unstructured":"World Health Organization. HEARTS: technical package for cardiovascular disease management in primary health care. Geneva: WHO; 2016. Available from: https:\/\/iris.who.int\/handle\/10665\/252661."},{"key":"ref3","unstructured":"World Health Organization. Guideline for the pharmacological treatment of hypertension in adults. Geneva: WHO; 2021. Available from: https:\/\/iris.who.int\/handle\/10665\/344424."},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Al-Makki A, DiPette D, Whelton PK, Murad MH, Mustafa RA, Acharya S, et al. Hypertension pharmacological treatment in adults: a World Health Organization guideline executive summary. Hypertension. 2022;79(1):293\u2013301. https:\/\/doi.org\/10.1161\/hypertensionaha.121.18192.","DOI":"10.1161\/HYPERTENSIONAHA.121.18192"},{"key":"ref5","unstructured":"Pan American Health Organization. Integrated health service delivery networks: concepts, policy options and a road map for implementation in the Americas. Washington, D.C.: PAHO; 2011. Available from: https:\/\/iris.paho.org\/handle\/10665.2\/31323."},{"key":"ref6","unstructured":"Pan American Health Organization. Policy on integrated care for improved health outcomes [Document CE170\/16]. 170th Session of the PAHO Executive Committee; 20\u201324 June 2022. Washington, D.C.: PAHO; 2022. Available from: https:\/\/iris.paho.org\/handle\/10665.2\/62739."},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Proctor E, Silmere H, Raghavan R, Hovmand P, Aarons G, Bunger A, et al. Outcomes for implementation research: conceptual distinctions, measurement challenges, and research agenda. Adm Policy Ment Health. 2011;38(2):65\u201376. https:\/\/doi.org\/10.1007\/s10488-010-0319-7.","DOI":"10.1007\/s10488-010-0319-7"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Bigdeli M, Jacobs B, Tomson G, Laing R, Ghaffar A, Dujardin B, et al. Access to medicines from a health system perspective. Health Policy Plan. 2013;28(7):692\u2013704. https:\/\/doi.org\/10.1093\/heapol\/czs108.","DOI":"10.1093\/heapol\/czs108"},{"key":"ref9","unstructured":"Hogerzeil HV, Mirza Z. The world medicines situation 2011: Access to essential medicines as part of the right to health. Geneva: World Health Organization; 2011. Available from: https:\/\/scispace.com\/pdf\/the-world-medicines-situation-2011-access-to-essential-1q1b15ldpk.pdf."},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Wirtz VJ, Hogerzeil HV, Gray AL, Bigdeli M, de Joncheere CP, Ewen MA, et al. Essential medicines for universal health coverage. Lancet. 2017;389(10067):403\u2013476. https:\/\/doi.org\/10.1016\/S0140-6736(16)31599-9.","DOI":"10.1016\/S0140-6736(16)31599-9"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Peacocke EF, Myhre SL, Foss HS, Gopinathan U. National adaptation and implementation of the WHO Model List of Essential Medicines: a qualitative evidence synthesis. PLoS Med. 2022;19(3):e1003944. https:\/\/doi.org\/10.1371\/journal.pmed.1003944.","DOI":"10.1371\/journal.pmed.1003944"},{"key":"ref12","unstructured":"World Health Organization. The selection and use of essential medicines: report of the WHO Expert Committee on selection and use of essential medicines, 2023. Geneva: WHO; 2023. (WHO Technical Report Series, No. 1049). Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240089266."},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Londo\u00f1o E, Gupta R, Van der Stuyft P, Heine M, Giraldo G, Ku GM, et al. HEARTS quality: a policy framework to strengthen hypertension and cardiovascular risk management in primary healthcare\u2014insights from HEARTS in the Americas. Lancet Reg Health Am. 2026;53:101311. https:\/\/doi.org\/10.1016\/j.lana.2025.101311.","DOI":"10.1016\/j.lana.2025.101311"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Souza KM, Giron N, Vallini J, Hallar K, Ordunez P, Rosende A, et al. Barriers to access to antihypertensive medicines: insights from the HEARTS initiative in Latin American and Caribbean region. J Pharm Policy Pract. 2024;17(1):2379045. https:\/\/doi.org\/10.1080\/20523211.2024.2379045.","DOI":"10.1080\/20523211.2024.2379045"},{"key":"ref15","unstructured":"Pan American Health Organization. PAHO study highlights challenges in access to hypertension medication in Latin America and the Caribbean. Washington, D.C.: PAHO; 2024 [cited 2026 Apr 24]. Available from: https:\/\/www.paho.org\/en\/news\/26-8-2024-paho-study-highlights-challenges-access-hypertension-medication-latin-america-and."},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Yadav P. Health product supply chains in developing countries: diagnosis of the root causes of underperformance and an agenda for reform. Health Syst Reform. 2015;1(2):142\u2013154. https:\/\/doi.org\/10.4161\/23288604.2014.968005.","DOI":"10.4161\/23288604.2014.968005"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Wagenaar BH, Gimbel S, Hoek R, Pfeiffer J, Michel C, Manuel JL, et al. Stock-outs of essential health products in Mozambique \u2013 longitudinal analyses from 2011 to 2013. Trop Med Int Health. 2014;19:791\u2013801. https:\/\/doi.org\/10.1111\/tmi.12314.","DOI":"10.1111\/tmi.12314"}],"container-title":["Revista Panamericana de Salud P\u00fablica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/iris.paho.org\/bitstreams\/39c8e945-9dbd-486d-9b49-d8131f7ac24c\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T14:29:08Z","timestamp":1788186548000},"score":1,"resource":{"primary":{"URL":"https:\/\/iris.paho.org\/handle\/10665.2\/72107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":17,"alternative-id":["RPSP.2026.76"],"URL":"https:\/\/doi.org\/10.26633\/rpsp.2026.76","relation":{},"ISSN":["1020-4989","1680-5348"],"issn-type":[{"value":"1020-4989","type":"print"},{"value":"1680-5348","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]}}}